Results 21 to 30 of about 3,573,509 (380)

Protease inhibitors targeting coronavirus and filovirus entry [PDF]

Antiviral Research, 2015
In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins by host cell proteases.
Yanchen Zhou, P. Vedantham, Kai Lu, J. Agudelo, R. Carrion, Jerritt W. Nunneley, D. Barnard, S. Pöhlmann, J. McKerrow, A. Renslo, G. Simmons   +10 more
semanticscholar   +3 more sources

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

bioRxiv, 2022
Vaccines and drugs have helped reduce disease severity and blunt the spread of SARS-CoV-2. However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these
S. Moghadasi, E. Heilmann, A. Khalil, Christina Nnabuife, Fiona L. Kearns, C. Ye, Sofia N. Moraes, Francesco Costacurta, M. Esler, H. Aihara, D. Laer, L. Martínez-Sobrido, T. Palzkill, Rommie E. Amaro, R. Harris   +14 more
semanticscholar   +1 more source

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay

Communications Biology, 2022
SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug development. In this study, we present an antiviral screening strategy involving a novel in-cell protease assay, antiviral and biochemical activity assessments, as well as ...
Anoop Narayanan, M. Narwal, Sydney A. Majowicz, C. Varricchio, Shay A Toner, C. Ballatore, A. Brancale, K. Murakami, J. Jose   +8 more
semanticscholar   +1 more source

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Nature Communications, 2021
We report the identification of three structurally diverse compounds – compound 4, GC376, and MAC-5576 – as inhibitors of the SARS-CoV-2 3CL protease.
S. Iketani, F. Forouhar, Hengrui Liu, Seo Jung Hong, F. Lin, M. Nair, A. Zask, Yaoxing Huang, L. Xing, B. Stockwell, A. Chavez, D. Ho   +11 more
semanticscholar   +1 more source

Comparative study of the unbinding process of some HTLV-1 protease inhibitors using unbiased molecular dynamics simulations.

PLoS ONE, 2022
The HTLV-1 protease is one of the major antiviral targets to overwhelm this virus. Several research groups have developed protease inhibitors, but none has been successful.
Fereshteh Noroozi Tiyoula, Hassan Aryapour, Mostafa Javaheri Moghadam   +2 more
doaj   +1 more source

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Frontiers in Chemistry, 2021
The Coronavirus disease-19 (COVID-19) pandemic is still devastating the world causing significant social, economic, and political chaos. Corresponding to the absence of globally approved antiviral drugs for treatment and vaccines for controlling the ...
H. M. Mengist, Tebelay Dilnessa, T. Jin
semanticscholar   +1 more source

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Science, 2020
Targeting a key enzyme in SARS-CoV-2 Scientists across the world are working to understand severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). Zhang et al.
Linlin Zhang, Daizong Lin, Xinyuanyuan Sun, U. Curth, C. Drosten, Lucie Sauerhering, S. Becker, K. Rox, R. Hilgenfeld   +8 more
semanticscholar   +1 more source

HIV Protease: Historical Perspective and Current Research

Viruses, 2021
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by ...
Irene T. Weber, Yuan-Fang Wang, Robert W. Harrison   +2 more
doaj   +1 more source

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Nature Communications, 2020
The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases potentially targetable with antivirals.
J. Osipiuk, S. Azizi, Steve Dvorkin, M. Endres, R. Jedrzejczak, Krysten A. Jones, Soowon Kang, R. Kathayat, Youngchang Kim, V. Lisnyak, S. Maki, V. Nicolaescu, Cooper A. Taylor, C. Tesar, Yu-an Zhang, Zhiyao Zhou, G. Randall, K. Michalska, S. Snyder, B. Dickinson, A. Joachimiak   +20 more
semanticscholar   +1 more source

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Cell Research, 2020
A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around December 2019, and it is now widespread as a global pandemic.
Chunlong Ma, M. Sacco, B. Hurst, J. A. Townsend, Yanmei Hu, Tommy Szeto, Xiujun Zhang, Bart Tarbet, M. Marty, Yu Chen, Jun Wang   +10 more
semanticscholar   +1 more source